1 Transcriptomic signature on Hantavirus Cardiopulmonary Syndrome 2 patients, reveals an increased interferon response as a hallmark of critically ill 3 patients

4
5 Grazielle E. Ribeiro ¹, Eduardo Duran-Jara ¹, Ruth Perez ¹, Analia Cuiza ¹, Luis E. Leon ²,
6 Constanza Martínez-Valdebenito ³, Nicole Le Corre ³, Marcela Ferres ³, Leonila Ferreira⁴, Maria
7 Luisa Rioseco⁵, Jorge Gavilán⁶, Francisco Arancibia⁶, Jerónimo Graf ⁷, Rene Lopez⁷, Jose Luis
8 Perez⁸, Mario Calvo⁹, Gregory J Mertz¹⁰, Pablo A. Vial ^{1,11}, Cecilia Vial ^{1*} and the hantavirus
9 study group.

10 ¹ Instituto de Ciencias e Innovación en Medicina, Facultad de Medicina, Clínica Alemana
11 Universidad del Desarrollo, Santiago, Chile

12 ² Instituto de Ciencias Biomédicas, Facultad de Ciencias de la Salud, Universidad Autónoma de
13 Chile, Santiago, Chile

14 ³ Departamento de Enfermedades Infecciosas e Inmunología Pediátricas, Pontificia Universidad
15 Católica de Chile, Santiago, Chile

16 ⁴ Hospital Dr. Guillermo Grant Benavente Concepción, Concepción, Chile

17 ⁵ Hospital Puerto Montt Dr. Eduardo Schütz Schroeder, Puerto Montt, Chile

18 ⁶ Instituto Nacional del Tórax, Santiago, Chile

19 ⁷ Departamento de Paciente Crítico, Clínica Alemana de Santiago, Santiago, Chile

20 ⁸ Hospital Base San José de Osorno, Osorno, Chile.

21 ⁹ Instituto de Medicina, Universidad Austral de Chile - Hospital Base Valdivia, Valdivia, Chile.

22 ¹⁰ Department of Internal Medicine, University of New Mexico, Albuquerque, USA

23 ¹¹ Departamento Pediatría Clínica Alemana de Santiago, Santiago, Chile

24
25 * Correspondence: mcvial@udd.cl; Tel.: +56225-785-772.

26
27 **Short Title:** Transcriptome analysis in HCPS patients

28
29 **Abstract:** New World hantaviruses are important human pathogens that can cause a severe
30 zoonotic disease called hantavirus cardiopulmonary syndrome (HCPS). HCPS patients can
31 progress quickly to a severe condition with respiratory failure and cardiogenic shock that can be
32 fatal in 30% of the cases. The role of the host's immune responses in this progression towards
33 HCPS remains elusive. In this study, 12 patients hospitalized with severe HCPS were analyzed
34 using a transcriptome approach combined with clinical laboratory data to gain a better insight
35 into factors associated with a severe clinical course. Patients were further classified in two levels

36 of severity, a first group that required mechanical ventilation and vasoactive drugs (VM+VD)
 37 and a second group that also needed ECMO or died (ECMO/Fatal). Their transcriptional profile
 38 was compared during acute (early and late) and convalescent phases. Our results showed that
 39 overexpression of the interferon response is correlated with a worse (ECMO/Fatal) outcome and
 40 an increased viral load and proinflammatory cytokines in the early-acute-phase. This report
 41 provides insights into the differences in innate immune activation between severe patients that
 42 associates with different clinical outcomes, using a non-biased approximation.

43

44 **Author Summary:** Hantavirus are rodent-borne zoonotic pathogens that when transmitted to
 45 humans cause two diseases: hantavirus renal syndrome in Europe and Asia, and hantavirus
 46 cardiopulmonary syndrome (HCPS) in the Americas. The latter, the goal of this work, is a
 47 highly lethal disease with a case fatality rate of 30%. Moreover no specific treatment or vaccine
 48 is available for this disease. In this study, we analyzed hospitalized HCPS patients with severe
 49 disease, to understand how they respond to hantavirus infection. We used a method that can
 50 measure every mRNA that is being transcribed in one moment (transcriptome analysis) and thus
 51 provide an accurate idea of how cells (specifically peripheral blood mononuclear cells) are
 52 responding to infection. The knowledge gained in this study helps us further understand the
 53 pathogenesis of this disease and might help us to design specific therapies to treat it.

54

55 **Introduction**

56

57 *Orthohantavirus* (known as hantaviruses) is a family of single-stranded, enveloped,
 58 negative-sense RNA viruses that belong to the *Hantaviridae* family of the order *Bunyavirales*[1].

59 Pathogenic Orthohantaviruses can cause two severe human zoonotic diseases: hemorrhagic fever
60 with renal syndrome (HFRS) in Europe and Asia and hantavirus cardiopulmonary syndrome
61 (HCPS) on the American continent, with a case fatality rate up to 30% [2]. *Andes*
62 *orthohantavirus* (ANDV) is one of South American HCPS causing hantavirus and the only
63 hantavirus that is known to transmit from person to person [3,4]. After an individual gets
64 infected, the incubation period lasts from seven to 42 days [5,6]. Then a prodromal phase of
65 three to six days starts characterized by nonspecific symptoms including fever, headache and
66 myalgia. Patients may progress to the cardiopulmonary phase which in severe disease is
67 characterized by respiratory symptoms that start with dry cough and evolve to respiratory failure
68 needing mechanical ventilation due to a massive capillary leak into the lung interstitium [7,8].
69 Severe patients present with circulatory shock and cardiovascular depression that require use of
70 vasoactive drugs [7,9]. Since there is not a vaccine for this deadly disease nor a specific
71 treatment, treatment is based on critical care support. A proportion of these severe patients have
72 a more critical illness that needs extracorporeal membrane oxygenation (ECMO) support and
73 about one third die.

74 A common hallmark of HCPS is the increased immune activation and vascular
75 permeability that develops during the cardiopulmonary phase producing pulmonary edema and
76 cardiogenic shock in the most severe cases [7]. Viremia is present during the incubation period
77 for up to two weeks before onset of symptoms or appearance of IgM and IgG antibodies [3].
78 Orthohantaviruses systemically infect and replicate predominantly in endothelial cells (ECs)
79 [10,11], but can also infect epithelial and immune cells such as monocytes/macrophages and
80 dendritic cells [10,12–18]. Hantaviruses do not cause a cytopathic effect [10,11] suggesting that
81 their pathogenic effects are caused rather by the host immune response during infection, which

includes a cytokine storm [19]. Increased serum levels of proinflammatory cytokines, such as IL-6, IFN- γ and TNF- α , along with high infiltration of mononuclear cells, mainly CD4⁺ and CD8⁺ T lymphocytes in the lung, are associated with a severe outcome [20–22].

The innate immune response, which is the first reaction to a viral infection, could be one crucial step that modifies how the infected individual will respond to the virus. The regulation of the complement system, a significant component of innate immunity, could also influence the clinical course since deletion in regulatory genes (CFHR1 and CFHR3) have been found to be more frequent in severe HCPS patients [23].

The role of the host's immune responses in the progression of HCPS and their association with severity remains elusive. In this study, we applied a non-biased, transcriptome approach combined with clinical laboratory data in a cohort of ANDV-infected patients that developed a severe clinical course to explore the factors associated with HCPS severity.

This report provides a comprehensive description of innate immune programs active in PBMCs during acute HCPS patients. Increased type I IFN response, specifically the overexpression of interferon-induced genes (ISGs), is associated with a more severe outcome, defined as patients requiring ECMO or died, and to increased viral load in Peripheral Blood Mononuclear Cells (PBMCs) and increased proinflammatory cytokines levels in serum.

Results

Characterization of studied participants

Twelve patients, nine males and three females, with severe HCPS were analyzed in this

105 study. They had a median age of 27, nine being of European ancestry and three with Amerindian
 106 ancestry. The 12 HCPS patients were further reclassified into two groups according to their
 107 severity: MV+VD ($n=5$) were those who received mechanical ventilation (MV) and vasoactive
 108 drugs (VD) as treatment, and ECMO/Fatal ($n=7$) were those patients that also received ECMO as
 109 a treatment or died. The healthy control group ($n=9$) consisted of four females and five males
 110 with a median age of 25 years. There was no difference between groups when comparing
 111 demographic data (Table 1). Clinical data including days of oxygen requirement, vasoactive
 112 drugs, mechanical ventilation, ECMO treatment, and hospitalization days were available for the
 113 cohort (Table 1). These values were similar between study groups except for the days in
 114 mechanical ventilation. White blood cells and platelet count, ANDV viral load in PBMCs,
 115 together with sub-population immunophenotyping of the earliest measurement (up to 48 hours
 116 after onset of cardiopulmonary symptoms) were also compared for these groups. There was no
 117 difference between groups on viral load, total leukocyte number, or neutrophil percentage,
 118 although a tendency of increase in viral load and a decrease in leukocyte count was observed in
 119 the ECMO/Fatal patients (Table 1). A significant difference was found in platelet count in the
 120 two HCPS groups compared to healthy controls, as previously described [24]. The blood
 121 immune cell populations were evaluated by flow cytometry in the first sample from each patient
 122 as described in the methods section. Although no significant difference was found, a trend
 123 towards an increase in T helper cells, CD56^{Bright} NK cells and NKT cells, and a tendency for a
 124 decrease in cytotoxic T cells, NK cells, and B cells was observed in ECMO/Fatal patients
 125 compared to MV+VD ones.

126 The complete clinical course of the 12 HCPS patients in this study along with samples
 127 obtained is represented in Fig 1. The prodromic phase with non-specific symptoms varied

128 between three to ten days, and day 0 represents the onset of cardiopulmonary symptoms. Blood
129 samples were collected during the acute phase (early acute between the days 0-2 and late acute
130 samples between days 5-6 after the onset of cardiopulmonary symptoms). One last blood sample
131 was collected in the convalescent-phase (day >60 after cardiopulmonary symptoms onset).
132 Patients that only required mechanical ventilation and vasoactive drugs during their
133 hospitalization were grouped in the MV+VD patients group. Patients requiring ECMO or that
134 died were grouped together in the more severe ECMO/Fatal group of patients.

135

136 **PBMC transcriptome profile of HCPS patients by severity and clinical phase**

137

138 Total PBMC samples sequenced and analyzed are detailed in S1 Table. Briefly, after
139 quality control filters, 16,187 genes were included in subsequent analyses. First, a
140 multidimensional scaling (MDS) was performed to evaluate the global gene expression patterns
141 between the samples to determine which variable explained the difference in the data. In MDS
142 analysis two groups were observed: one integrated by healthy controls and convalescent-phase
143 subjects and another group of acute-phase patients (Fig 2A). These results show that the greatest
144 variability in subject's gene expression was produced by the infection itself. Interestingly, there
145 was no clear separation between MV+VD and ECMO/Fatal patients in early or late-acute-phase.

146 Differential gene expression was conducted with the limma-voom analysis workflow using
147 Benjamini and Hochberg (BH) correction for multiple testing. Differential expression analysis
148 was performed by comparing samples from MV+VD and ECMO/Fatal HCPS patients in an
149 early-acute, late-acute, and convalescent-phase with healthy controls. The total of differentially
150 expressed genes (DEGs) in the MV+VD group was 277 in early and 109 in late-acute-phase; and

151 in ECMO/Fatal group DEGs were 310 in early and 342 in late-acute-phase (Fig 2B). IFI27 was
152 the most overexpressed gene with highest Log2FC and lowest p-value in both groups of severe
153 patients during the acute phase. Interestingly, proinflammatory cytokines, such as IL-6 and
154 TNF- α , that are known to be increased in serum of severe HCPS patients, were not differentially
155 expressed in MV+VD or ECMO/Fatal patients at any time when compared to healthy controls.
156 Taken together, these results suggest that the increased serum levels of these cytokines could be a
157 contribution of other cell types, such as endothelial cells and macrophages, rather than PBMCs.
158 There were no statistically significant DEGs in the convalescent-phase when compared with
159 healthy controls (Fig 2B). This suggests that at the convalescent-phase, patients have resolved
160 the disease in terms of level of gene expression. At the level of clinical symptoms, some patients
161 continued to be hospitalized because of ECMO complications, others experienced fatigue and
162 mild respiratory distress at day 60, but the majority had returned to normal life. Fig 2C shows the
163 expression profile of MV+VD and ECMO/Fatal HCPS patients at every time point. The total of
164 439 DEGs were plotted in the heatmap. ECMO/Fatal patients showed a different signature
165 compared to MV+VD patients during the acute phase in both early and late timepoints. As
166 expected, HCPS patients in the convalescent-phase presented a pattern of expression similar to
167 healthy controls. The number of shared and unique DEGs between MV+VD and ECMO/Fatal
168 patients in an early and late acute-phase are shown in a Venn diagram (Fig 2D). There were 58
169 genes differentially expressed only in MV+VD patients in an early-acute phase and 2 in a
170 late-acute phase and 52 in ECMO/Fatal patients in an early-acute and 89 in a late-acute phase
171 (Fig 2D). Ninety-one genes were shared throughout all conditions (MV+VD and ECMO/Fatal in
172 an early and late-acute phase) compared to healthy controls (Fig 2D).

173

174 Gene set enrichment analysis by severity and clinical phase

175

176 To further define the biological function and pathways associated with a severe clinical
177 course, we applied a gene set enrichment analysis called blood transcriptome module (BTM) as
178 described [25,26]. BTMs are groups of genes that share a similar function, where BTM up- and
179 downregulation is defined by the percentage of genes within each module that are differentially
180 expressed. Activation of modules was tested comparing each study group to healthy controls and
181 using the FDR-ranked lists of DEGs generated by limma and applying the tmod test. The BTMs
182 with a $p\text{-value} \leq 0.001$ were considered significant. When HCPS patients were analyzed together,
183 a strong upregulation of Modules that group genes with functions in cell cycle, DNA repair,
184 mitosis was observed (data not shown), which can be further observed when patients are
185 re-classified in MV+VD and ECMO/Fatal groups (Fig 3). Moreover, this response is still active
186 during the late-acute-phase but returns to normal values during convalescence. The enrichment
187 observed in these pathways points to the immune activation that is taking place in both groups of
188 severe patients and the lymphoid proliferation that is taking place during the acute-phase of the
189 disease. On the other hand, when all HCPS patients were analyzed together, modules that
190 grouped genes from the innate immune response were enriched during the early phase of the
191 acute disease (data not shown). When these severe patients were reclassified as MV+VD and
192 ECMO/Fatal, this association was only seen in the more severe group (ECMO/Fatal) during the
193 early-acute phase (Fig 3, marked with arrows). These BTMs include a greater activation in
194 antiviral IFN signature, IFN I signalling and innate antiviral response, activation in B cells and
195 plasma cells and BTMS of activated dendritic cells. The comparison of expression of the
196 significant genes belonging to these innate immune response marked modules, are shown in S2

Table. This data suggests that in ANDV-infected patients that develop HCPS, there is a strong innate immune response that is greater in the most severe ECMO/Fatal HCPS group of patients. Interestingly, these more severe ECMO/Fatal patients have an over-representation of innate immune pathways, especially genes participating in the interferon signaling pathway.

DEGs in MV+VD and ECMO/Fatal HCPS patients in early-acute phase

Once the functions of all DEGs between MV+VD and ECMO/Fatal patients in an early-late acute phase were described, unique genes for each severity group were analyzed. One of the interests of the study was to understand the factors associated with critical clinical courses at the onset of the cardiopulmonary phase, so further analyses were focused on unique DEGs of the early-acute phase. Transcriptional profiles of 110 genes that include 52 genes that were detected to be uniquely differentially expressed in ECMO/Fatal patients and 58 genes detected in MV+VD patients were analyzed. Fig 4 shows a clear difference in the expression profile of these genes between patients of different severities and healthy controls.

To evaluate the functions of these unique DEGs, a gene set enrichment analysis was performed separately for each group of genes (58 for MV+VD and 52 ECMO/Fatal). This method uses statistical approaches to identify significantly enriched or depleted groups of genes that participate in the same biological process. Thus, the functions which are exclusively altered in each group can be identified. No biological processes were found to be enriched in MV+VD patients compared to healthy controls. However, seven biological processes were enriched in ECMO/Fatal patients. These biological processes were mainly from innate immune response, primarily type I interferon response (Fig 4B). The detail of the genes belonging to these

biological processes is in the S3 Table. These results showed that genes associated with innate immune response, especially type I interferon response, were enriched only in ECMO/Fatal patients. This is in concordance to what was found on BTM analysis.

Correlation between expression of BTM enriched exclusively in ECMO/Fatal patients and clinical laboratory data

To assess whether the expression of the genes from enriched BTMs in ECMO/Fatal patients in an early-acute-phase could impact the severity and clinical laboratory parameters, the expression of these BTMs was correlated with these patients' laboratory data (Fig 5 and detail in S4 Table). The BTMs associated with interferon response, including antiviral interferon signature (LI.M75), type I interferon response (LI.M127) and innate antiviral response (LI.M150); dendritic cells: activated dendritic cells (LI.M67) and enriched in activated dendritic cells (LI.M165); and plasma cells surface signature (LI.S3), showed a statistically positive correlation with ECMO/Fatal clinical course (Fig 5). The BTMs associated with interferon response (LI.M75, LI.M127, and LI.M150) are positively correlated with viral load, amount of NK cells and TNF- α serum levels. LI.M127 and LI.M150 are also positively correlated with the amount of NKT cells and IL-6 serum levels and negatively correlated with neutrophils percentage. The BTM activated dendritic cells (LI.M67) is positively correlated with NK cells, viral load, amount of NK, and Th cells. Platelets, leukocytes, CD3+, CD8+, CD56^{Bright} NK cells did not show any statistically significant correlation with the enriched BTMs. Thus, the overexpression of interferon response genes is correlated with a ECMO/Fatal outcome and an increased viral load in PBMCs and proinflammatory cytokines (IL-6 and TNF- α) serum levels

243 and could be contributing to immunopathogenesis instead of restricting viral replication. Having
244 an increased type I interferon response appears to correlate to poor prognosis in HCPS patients.

245

246 Discussion

247

248 The host immune response is an important mechanism in the pathogenesis of HCPS. An
249 exaggerated and uncontrolled activation of the innate and adaptive immune response is
250 associated with severity [20,27–31]. In this study, we applied a transcriptome approach
251 combined with clinical laboratory data to gain a better insight into factors associated with HCPS
252 critical or fatal clinical course.

253 The human innate immune response, particularly type-I IFN response, is a highly robust
254 and effective first line of defense against virus invasion. In infected and neighboring cells, type I
255 IFNs induce the expression of IFN-stimulated genes (ISGs), the products of which initiate an
256 intracellular antimicrobial program that limits the spread of infectious agents [32,33]. Failure to
257 mount an effective IFN response against the virus leads to systemic infection, while excessive
258 IFN production leads to pathogenicity, severe symptoms, or even fatality [34–36].

259 Our findings demonstrated that PBMCs transcriptome from the more severe ECMO/Fatal
260 HCPS group of patients have a greater activation of the innate immune response in the earliest
261 stages of the cardiopulmonary phase than in less severe MV+VD patients. BTMs associated with
262 IFN response, dendritic, and plasma cells were enriched in the ECMO/Fatal patients between 0
263 to 2 days after cardiopulmonary symptoms started. They also had upregulated genes associated
264 with type I interferon response, whose main function is to negatively regulate viral replication
265 (i.e., USP18, ISG15, IFIT3, IFIT1, MX1, IF6, IFI44L, IFITM3 and Siglec-1). In other viral

infections, such as Coronavirus disease 19 (COVID-19), severe patients have recently been characterized of having an up-regulation of various ISGs, including ISG15, IFITM1/2/3, and ISG20[31]; so, these unregulated type I IFN responses could be an important hallmark for severity in viral respiratory diseases. Interestingly, the BTMs enriched in the ECMO/fatal HCPS patients associated with type I IFN response (LI.M75, LI.M127, and LI.M150) were positively correlated with high viral load, proinflammatory cytokines (IL-6 and TNF- α) serum levels and ECMO/Fatal clinical course. BTM associated with dendritic cells (LI.M67, LI.M165) were also positively correlated with viral load and ECMO/Fatal clinical course. This means that the higher the expression of type I IFN genes, the greater the viral load and proinflammatory response and consequently greater illness severity. Because the overexpression of interferon response genes is associated with a critical and fatal outcome, an increase in viral load in PBMCs and an increase in proinflammatory cytokines serum levels, it could rather be contributing to immunopathogenesis rather than restricting viral replication in these patients.

It has been known for decades that viruses evolve different strategies to escape the type I IFN response in order to replicate and disseminate successfully in their hosts [37]. *In vitro* experiments have shown that pathogenic hantaviruses can block early IFN responses, which favor an early viral replication in target cells, but later induce high-level ISG responses (1–4 days after infection) [13,38,39]. These observations correlate with HCPS natural history in which there is a long incubation period that can last up to 49 days, and viremia can be detected during this period up to 15 days before symptoms onset, suggesting a long escape of the virus to IFN response.

Moreover, *in vivo* experiments have shown that the treatment with IFN- β could increase the survival of Hantaan (HTNV) infected mice only if performed less than 24 hours after

infection [40]. In this study we have shown that despite a strong interferon response in the ECMO/fatal HCPS patients, there is no correlation with a decrease in viral load. The findings of this study suggest that insensitivity to the interferon response occurs in ECMO/fatal HCPS patients and correlates with poor prognosis in HCPS patients. The molecular mechanisms by which hantaviruses become insensitive to the interferon response, specifically how they evade the response to ISGs once the infection is already established, is not yet known and should be studied further.

The mechanisms by which type I interferon response promotes severity in viral infections remains controversial and elusive. A common theme is emerging in which type I IFN has the potential to over activate the immune system during acute viral infection. Besides the induction of ISGs, type I IFN also induces secretion of cytokines and chemokines and activation of pathways that allow the clearance of infected cells [41,42]. Therefore, the induction of proinflammatory cytokines or chemokines or activation of apoptosis-inducing pathways to clear virally infected cells, which were designed to be protective, can lead to tissue damage with serious consequences to the host [41,43]. HCPS is characterized by an exacerbated immune response that includes a “cytokine storm” that contributes to pathogenesis. In this sense increased serum levels of proinflammatory cytokines, such as IL-6, IFN- γ and TNF- α are associated with a severe HCPS outcome [20,22,44]. We found that the overexpression of ISGs is positively correlated with proinflammatory cytokines (IL-6 and TNF- α) serum levels. This suggests that increased type I IFN response could be contributing with the increase of proinflammatory response in the ECMO/fatal HCPS patients. Although these proinflammatory cytokines were not differentially expressed in severe or ECMO/Fatal patients when compared with healthy controls, the increased serum levels of these markers could be a contribution from

other cell types, such as endothelial cells or macrophages, rather than PBMCs. Thus, the overregulation of ISGs in PBMCs could be contributing to immunopathology altering inflammatory pathways in a paracrine way.

Our results provide insights into the dynamics of early and late PBMCs immune responses in HCPS patients and factors associated with ECMO/fatal clinical course. We found that the overexpression of type I IFN genes are positively correlated with increased viral load in PBMCs and proinflammatory cytokines and could contribute to immunopathogenesis rather than restricting viral replication in HCPS patients. Then, hantavirus IFN insensitivity together with exacerbated proinflammatory response induced by increased IFN response could contribute to ECMO/fatal HCPS outcome (Fig 6). These results suggest that treatment with interferon could worsen the HCPS clinical course. Future studies should investigate the damaging effects of type I IFN response to better understand the immunopathogenesis of HCPS.

Materials and methods

Ethics statement

This study was approved by the ethics committee of each participating institution, Clínica Alemana Universidad del Desarrollo (UDD) IRB4858, FWA8639, January 2016; Hospital Clínico UC, IRB2886, FWA4080, July 2016; Hospital Base Valdivia IRB1914 FWA 3412, January 2017, Hospital Base Osorno IRB1914 FWA 3412, January 2017; Hospital Regional Puerto Montt, IRB1914, FWA 3412, January 2016, Instituto Nacional del Tórax, April 11 2017. Enrolled subjects provided written informed consent, their parents, or legal guardians. Clinical data and stored samples were anonymized to ensure confidentiality.

335

336 **Study design**

337 Subjects were recruited in six research centers from central and southern regions of Chile
 338 between March, 2017, and June 2018. Hospitalized subjects with a suspected or confirmed
 339 diagnosis of ANDV infection by serology or RT-qPCR were invited to participate. Exclusion
 340 criteria included patients connected to extracorporeal membrane oxygenation (ECMO) at
 341 enrollment. A total of 24 HCPS patients were enrolled, eight were excluded for these analyses:
 342 one co-infected with Epstein-Barr virus, another one negatively diagnosed for HCPS, patients
 343 with a mild clinical course (not requiring vasoactive drugs or mechanical ventilation) or that did
 344 not complete follow up. A group of healthy subjects (controls) were also enrolled (n=9), and
 345 exclusion criteria included the presence of chronic disease, pregnancy or any signs and
 346 symptoms of an acute infection in the two weeks prior to enrollment. A schematic diagram of
 347 enrolled and analyzed patients is available in S1 Fig. The 12 severe HCPS patients analyzed
 348 were defined as those who develop cardiopulmonary failure and required vasoactive drugs and
 349 mechanical ventilation. Severe HCPS patients were further reclassified as MV+VD (n=5) for
 350 those who received only mechanical ventilation and vasoactive drugs as treatment and
 351 ECMO/Fatal (n=7) for those who also received ECMO as a treatment or died. The subjects were
 352 followed for sixty days post-enrollment. Two blood samples were collected during the acute
 353 phase and one sample in convalescent-phase (at least 60 days after onset of cardiopulmonary
 354 symptoms). A single sample was taken for healthy controls.

355

356 **Sample preparation and RNA-seq**

357 The PBMCs were separated by Ficoll-paque (Sigma Aldrich) following the manufacturer's

specifications. Aliquots of $1-3 \times 10^6$ PBMCs/mL were prepared and the RNA was stabilized with RNeasy Protect cell reagent (QIAGEN) and frozen at -80°C . The RNA was extracted using the RNeasy kit (Qiagen) following the manufacturer's specifications. The quality was assessed using the Agilent 2200 TapeStation. All samples exhibited RNA integrity numbers (RIN) greater than 6. Aliquots of 350 ng were prepared, stored at -80°C and shipped on dry ice to the Broad Institute (Boston, USA) for RNA sequencing. RNA-seq libraries were prepared with Illumina Truseq Stranded mRNA chemistry. Libraries were sequenced in multiplex on the Illumina HiSeq 2500 platform in 50M reads in pairs.

Viral Load and multiplex

For the viral load determination, total nucleic acids were extracted from the buffy coat obtained from 5mL of peripheral blood using High Pure Viral Nucleic Acid Kit (Roche) following the manufacturer's specifications. ANDV virus infections were determined by reverse transcription-polymerase chain reaction (RT-qPCR) using primers from the S segment as described previously[45] and the number of viral copies per total ng RNA was calculated. The serum levels of proinflammatory cytokines (IL-6, TNF- α) were measured using a MILLIPLEX map (HCYTOMAG-60K, Merk) following the manufacturer's instructions.

Transcriptome and BTM analysis

A total of 37 samples from 12 HCPS patients (five MV+VD and seven ECMO/Fatal in an early, late and convalescent-phase) and nine healthy controls were sequenced (S1 Table). Quality control of the sequenced reads was performed with FastQC. The low-quality sequences (score <30) and Illumina adapters were excluded using trimmomatic (v0.38)[46]. Reads were mapped

381 to the human genome reference (hg37) using the STAR (v2.7.0d)[47] alignment tool. Read
382 counts per gene were quantified against Ensembl (hg37) transcript reference annotations using
383 featureCounts (v1.6.2)[48]. Analysis was conducted within the Jupyter notebook using IRKernel
384 (v0.8.15) statistical framework. First, filters to remove samples with less than 10 million aligned
385 reads were applied. Only one sample of convalescent-phase from Severe type 1 patient did not
386 meet these quality criteria and was excluded from the analyzes. 36 sequenced samples passed
387 filter and were included in the following analysis (S1 Table). Second, RNA-Seq read counts were
388 scaled and normalized by differences in library size between samples using log2-counts per
389 million (log-CPM). Expressed genes were defined as genes with greater than one log-CPM in at
390 least four samples. Genes that did not meet this parameter were filtered. 16,187 genes passed the
391 filter. Third, the RNA-Seq read counts were normalized by composition bias which computes
392 normalization factors for comparing between libraries on a relative scale using the Trimmed
393 Mean of M-values (TMM) method[49] and log2 transformed using voom as previously
394 described[50]. log-CPM and TMM normalizations were performed with edgeR package
395 (v3.24.3)[51]. To assess the similarities and dissimilarities in global expression profile between
396 the samples Multi-dimensional scaling (MDS) was performed by limma package (v3.38.9)[52]
397 and plotted by plotMDS function. Differential expression (DE) was conducted with the
398 limma-voom analysis workflow as previously described[50] using Benjamini and Hochberg
399 (BH) correction for multiple testing. DE was performed to compare samples from MV+VD
400 early, late and convalescent; and ECMO/Fatal early, late, and convalescent versus healthy
401 controls. Differentially expressed genes (DEGs) were selected based on an adjusted p-value of
402 0.05 (FDR of 5 %) and exhibiting at least 2 log2 fold change ($\log_2\text{FC} > 2$) a difference in
403 expression levels. To identify the exclusive DEGs on each condition and those shared throughout

all conditions a Venn diagram was made using the VennDiagram (v1.6.20) package. The gene set enrichment was performed using the clusterProfiler (v3.14.3). Enriched biological processes with an adjusted p-value of 0.01 were considered statistically significant. The heatmaps were scaled (log2FC median centered) and clusterized by row and graphed by pheatmap package (v. 1.0.12). Blood transcriptome modules (BTM) enrichment analyses were conducted with tmod (v.a40)[53] using the tmodLimmaTest function. BTM gene memberships and annotations were obtained from Li et al[25]. BTMs with an adjusted p-value of 0.01 (FDR of 1 %) were considered statistically significant.

Blood immune cell populations

Blood samples (5 ml) were obtained in acid citrate dextrose (ACD) tubes (BD Vacutainer ACD Solution B; BD, Franklin Lakes, NJ) only on early-acute-phase and processed within 2 to 4 hours of collection. PBMCs were separated by Ficoll-paque (Sigma Aldrich) and stored at -80°C using CryoStor CS10 medium (STEM CELL technologies) until use. Thawed PBMCs were stained with different antibody panels for characterization of NK, T and B cells subpopulations (S5 Table) using BD Biosciences antibodies. PBMCs were rapidly unfrozen and washed with 10% FBS supplemented PBS, centrifuged at 1200 rpm, and resuspended in PBS-2% FBS. PBMCs were counted and $2.5-5.0 \times 10^5$ live PBMCs were used for antibody stainings. Stainings were performed at room temperature for 15 minutes protected from light. PBMCs viability was assessed with the Zombie Aqua Fixable Viability Kit (Biolegend® cat. 423102). After that, unbound antibodies were washed away two times and stained PBMCs were fixed with 200 μ L 2% paraformaldehyde. The acquisition was performed in a FACS Canto II flow cytometer (BD Biosciences) and the data was analyzed with FlowJo v10.0.7.

427

428 **Statistical analysis**

429 RNASeqPower program package (v3.0.1)[54] was used for sample size calculation, which was
 430 developed to estimate the statistical power necessary to identify differentially expressed genes
 431 from RNA-seq experiments. To estimate the sample size, the estimated power of 0.8, the
 432 coefficient of variation of 0.4, and an effect size of 1.75 were used. Considering these
 433 parameters, the number of patients required for differential expression analysis was 9 for each
 434 group. For the analysis of the patient's demographic and clinical characteristics, IBM SPSS
 435 Statistics v.26 was used. Shapiro normality test was applied, and the Mann-Whitney test was
 436 used for comparisons between two non-paired numeric variables and Kruskal-Wallis for three or
 437 more groups without normal distribution, and Chi-square test for qualitative variables. To assess
 438 the correlation between BTM expression and clinical data, the expression median of genes from
 439 BTMs for each patient and Log2FC were calculated. Spearman correlation was performed in the
 440 R program using cor() function and was graphed with gplots (v3.0.1.1).

441 **Acknowledgments:** Thank members of the Hantavirus Study Group in Chile who contributed to
 442 patient enrollment and follow-up, sample collection and data management are as follows:
 443 Catalina Infante, RN, Carolina Henríquez, RN (Departamento de Enfermedades Infecciosas e
 444 Inmunología Pediátricas, Pontificia Universidad Católica de Chile); Flavio Carrión, PhD,
 445 Rodrigo Pérez, BKin (Clínica Alemana de Santiago Universidad del Desarrollo), Pamela Silva,
 446 RN, Angélica Gavilán, MT, Iván Rodríguez, MT, Marina Opazo, MD (Hospital Dr, Guillermo
 447 Grant Benavente Concepción); Carola Osorio, MT, Paulina Miranda, RN, (Hospital Base
 448 Valdivia) María Paz Blanco, RN, Camila Bolados, RN, Catherine Bosnich, MT, Paulina
 449 Cárcamo, MT, Carolina Nuñez, EU (Hospital Puerto Montt Dr. Eduardo Schütz Schroeder);

450 Felipe Vargas, MT, (Hospital Base San José de Osorno);. Thanks Dr. Anne Bliss and Steven
451 Bradfute, for critical reading of the manuscript, and Dr. David Gorkin for critical review of the
452 bioinformatic pipeline. Funding: This research was funded by Fondecyt 1161447, Fondecyt
453 1201240, Redes 180195, Concurso Interno VRID UDD2018, Facultad de Medicina, Clínica
454 Alemana Universidad del Desarrollo.

455

456 **References:**

- 457 1. Abudurexiti A, Adkins S, Alioto D, Alkhovsky SV, Avšič-Županc T, Ballinger MJ, et al.
458 Taxonomy of the order Bunyavirales: update 2019. Arch Virol. 2019;164: 1949–1965.
- 459 2. Vaheri A, Strandin T, Hepojoki J, Sironen T, Henttonen H, Mäkelä S, et al. Uncovering the
460 mysteries of hantavirus infections. Nat Rev Microbiol. 2013;11: 539–550.
- 461 3. Ferres M, Vial P, Marco C, Yanez L, Godoy P, Castillo C, et al. Prospective evaluation of
462 household contacts of persons with hantavirus cardiopulmonary syndrome in Chile. J Infect
463 Dis. 2007;195: 1563–1571.
- 464 4. Martinez VP, Bellomo C, San Juan J, Pinna D, Forlenza R, Elder M, et al. Person-to-person
465 transmission of Andes virus. Emerg Infect Dis. 2005;11: 1848–1853.
- 466 5. Núñez JJ, Fritz CL, Knust B, Buttke D, Enge B, Novak MG, et al. Hantavirus Infections
467 among Overnight Visitors to Yosemite National Park, California, USA, 2012. Emerging
468 Infectious Diseases. 2014. pp. 386–393. doi:10.3201/eid2003.131581
- 469 6. Vial PA, Valdivieso F, Mertz G, Castillo C, Belmar E, Delgado I, et al. Incubation period of
470 hantavirus cardiopulmonary syndrome. Emerg Infect Dis. 2006;12: 1271–1273.
- 471 7. Manigold T, Vial P. Human hantavirus infections: epidemiology, clinical features,
472 pathogenesis and immunology. Swiss Med Wkly. 2014;144: w13937.
- 473 8. Mertz GJ, Hjelle B, Crowley M, Iwamoto G, Tomicic V, Vial PA. Diagnosis and treatment
474 of new world hantavirus infections. Curr Opin Infect Dis. 2006;19: 437–442.
- 475 9. Riquelme R, Riquelme M, Torres A, Rioseco ML, Vergara JA, Scholz L, et al. Hantavirus
476 pulmonary syndrome, southern Chile. Emerg Infect Dis. 2003;9: 1438–1443.
- 477 10. Mackow ER, Gavrillovskaya IN. Hantavirus regulation of endothelial cell functions.
478 Thromb Haemost. 2009;102: 1030–1041.
- 479 11. Pensiero MN, Sharefkin JB, Dieffenbach CW, Hay J. Hantaan virus infection of human
480 endothelial cells. J Virol. 1992;66: 5929–5936.

- 481 12. Rowe RK, Pekosz A. Bidirectional virus secretion and nonciliated cell tropism following
482 Andes virus infection of primary airway epithelial cell cultures. *J Virol.* 2006;80:
483 1087–1097.
- 484 13. Witkowski PT, Bourquain D, Bankov K, Auste B, Dabrowski PW, Nitsche A, et al.
485 Infection of human airway epithelial cells by different subtypes of Dobrava-Belgrade virus
486 reveals gene expression patterns corresponding to their virulence potential. *Virology.*
487 2016;493: 189–201.
- 488 14. Nagai T, Tanishita O, Takahashi Y, Yamanouchi T, Domae K, Kondo K, et al. Isolation of
489 haemorrhagic fever with renal syndrome virus from leukocytes of rats and virus replication
490 in cultures of rat and human macrophages. *J Gen Virol.* 1985;66 (Pt 6): 1271–1278.
- 491 15. Maes P, Clement J, Gavrilovskaya I, Van Ranst M. Hantaviruses: immunology, treatment,
492 and prevention. *Viral Immunol.* 2004;17: 481–497.
- 493 16. Markotić A, Hensley L, Daddario K, Spik K, Anderson K, Schmaljohn C. Pathogenic
494 hantaviruses elicit different immunoreactions in THP-1 cells and primary monocytes and
495 induce differentiation of human monocytes to dendritic-like cells. *Coll Antropol.* 2007;31:
496 1159–1167.
- 497 17. Raftery MJ, Kraus AA, Ulrich R, Krüger DH, Schönrich G. Hantavirus infection of
498 dendritic cells. *J Virol.* 2002;76: 10724–10733.
- 499 18. Marsac D, García S, Fournet A, Aguirre A, Pino K, Ferres M, et al. Infection of human
500 monocyte-derived dendritic cells by ANDES Hantavirus enhances pro-inflammatory state,
501 the secretion of active MMP-9 and indirectly enhances endothelial permeability. *Virol J.*
502 2011;8: 223.
- 503 19. Khaiboullina SF, St Jeor SC. Hantavirus immunology. *Viral Immunol.* 2002;15: 609–625.
- 504 20. Bondu V, Schrader R, Gawinowicz MA, McGuire P, Lawrence DA, Hjelle B, et al. Elevated
505 cytokines, thrombin and PAI-1 in severe HCPS patients due to Sin Nombre virus. *Viruses.*
506 2015;7: 559–589.
- 507 21. Mori M, Rothman AL, Kurane I, Montoya JM, Nolte KB, Norman JE, et al. High levels of
508 cytokine-producing cells in the lung tissues of patients with fatal hantavirus pulmonary
509 syndrome. *J Infect Dis.* 1999;179: 295–302.
- 510 22. Maleki KT, García M, Iglesias A, Alonso D, Ciancaglini M, Hammar U, et al. Serum
511 Markers Associated with Severity and Outcome of Hantavirus Pulmonary Syndrome. *J*
512 *Infect Dis.* 2019;219: 1832–1840.
- 513 23. Ribeiro GE, Leon LE, Perez R, Cuiza A, Vial PA, Ferres M, et al. Deletions in Genes
514 Participating in Innate Immune Response Modify the Clinical Course of Andes
515 Orthohantavirus Infection. *Viruses.* 2019;11. doi:10.3390/v11080680
- 516 24. López R, Vial C, Graf J, Calvo M, Ferrés M, Mertz G, et al. Platelet Count in Patients with

- 517 Mild Disease at Admission is Associated with Progression to Severe Hantavirus
518 Cardiopulmonary Syndrome. *Viruses*. 2019;11. doi:10.3390/v11080693
- 519 25. Li S, Rouphael N, Duraisingham S, Romero-Steiner S, Presnell S, Davis C, et al. Molecular
520 signatures of antibody responses derived from a systems biology study of five human
521 vaccines. *Nat Immunol*. 2014;15: 195–204.
- 522 26. Chaussabel D, Baldwin N. Democratizing systems immunology with modular
523 transcriptional repertoire analyses. *Nat Rev Immunol*. 2014;14: 271–280.
- 524 27. Sane J, Laine O, Mäkelä S, Paakkala A, Jarva H, Mustonen J, et al. Complement activation
525 in Puumala hantavirus infection correlates with disease severity. *Ann Med*. 2012;44:
526 468–475.
- 527 28. Rasmuson J, Pourazar J, Mohamed N, Lejon K, Evander M, Blomberg A, et al. Cytotoxic
528 immune responses in the lungs correlate to disease severity in patients with hantavirus
529 infection. *Eur J Clin Microbiol Infect Dis*. 2016;35: 713–721.
- 530 29. Ennis FA, Cruz J, Spiropoulou CF, Waite D, Peters CJ, Nichol ST, et al. Hantavirus
531 pulmonary syndrome: CD8+ and CD4+ cytotoxic T lymphocytes to epitopes on Sin
532 Nombre virus nucleocapsid protein isolated during acute illness. *Virology*. 1997;238:
533 380–390.
- 534 30. Kilpatrick ED, Terajima M, Koster FT, Catalina MD, Cruz J, Ennis FA. Role of specific
535 CD8+ T cells in the severity of a fulminant zoonotic viral hemorrhagic fever, hantavirus
536 pulmonary syndrome. *J Immunol*. 2004;172: 3297–3304.
- 537 31. Lee JS, Park S, Jeong HW, Ahn JY, Choi SJ, Lee H, et al. Immunophenotyping of
538 COVID-19 and influenza highlights the role of type I interferons in development of severe
539 COVID-19. *Sci Immunol*. 2020;5. doi:10.1126/sciimmunol.abd1554
- 540 32. Huang Y, Dai H, Ke R. Principles of Effective and Robust Innate Immune Response to Viral
541 Infections: A Multiplex Network Analysis. *Front Immunol*. 2019;10: 1736.
- 542 33. Ivashkiv LB, Donlin LT. Regulation of type I interferon responses. *Nat Rev Immunol*.
543 2014;14: 36–49.
- 544 34. Baskin CR, Bielefeldt-Ohmann H, Tumpey TM, Sabourin PJ, Long JP, García-Sastre A, et
545 al. Early and sustained innate immune response defines pathology and death in nonhuman
546 primates infected by highly pathogenic influenza virus. *Proc Natl Acad Sci U S A*.
547 2009;106: 3455–3460.
- 548 35. Yockey LJ, Jurado KA, Arora N, Millet A, Rakib T, Milano KM, et al. Type I interferons
549 instigate fetal demise after Zika virus infection. *Sci Immunol*. 2018;3.
550 doi:10.1126/sciimmunol.aao1680
- 551 36. Liu X, Speranza E, Muñoz-Fontela C, Haldenby S, Rickett NY, Garcia-Dorival I, et al.
552 Transcriptomic signatures differentiate survival from fatal outcomes in humans infected

- 553 with Ebola virus. *Genome Biol.* 2017;18: 4.
- 554 37. Beachboard DC, Horner SM. Innate immune evasion strategies of DNA and RNA viruses.
555 *Curr Opin Microbiol.* 2016;32: 113–119.
- 556 38. Geimonen E, Neff S, Raymond T, Kocer SS, Gavrilovskaya IN, Mackow ER. Pathogenic
557 and nonpathogenic hantaviruses differentially regulate endothelial cell responses. *Proc Natl*
558 *Acad Sci U S A.* 2002;99: 13837–13842.
- 559 39. Matthys V, Mackow ER. Hantavirus regulation of type I interferon responses. *Adv Virol.*
560 2012;2012: 524024.
- 561 40. Tamura M, Asada H, Kondo K, Takahashi M, Yamanishi K. Effects of human and murine
562 interferons against hemorrhagic fever with renal syndrome (HFRS) virus (Hantaan virus).
563 *Antiviral Res.* 1987;8: 171–178.
- 564 41. Goritzka M, Durant LR, Pereira C, Salek-Ardakani S, Openshaw PJM, Johansson C.
565 Alpha/beta interferon receptor signaling amplifies early proinflammatory cytokine
566 production in the lung during respiratory syncytial virus infection. *J Virol.* 2014;88:
567 6128–6136.
- 568 42. Davidson S, Maini MK, Wack A. Disease-promoting effects of type I interferons in viral,
569 bacterial, and coinfections. *J Interferon Cytokine Res.* 2015;35: 252–264.
- 570 43. Davidson S, Crotta S, McCabe TM, Wack A. Pathogenic potential of interferon $\alpha\beta$ in acute
571 influenza infection. *Nat Commun.* 2014;5: 3864.
- 572 44. Angulo J, Martínez-Valdebenito C, Marco C, Galeno H, Villagra E, Vera L, et al. Serum
573 levels of interleukin-6 are linked to the severity of the disease caused by Andes Virus. *PLoS*
574 *Negl Trop Dis.* 2017;11: e0005757.
- 575 45. Vial C, Martinez-Valdebenito C, Rios S, Martinez J, Vial PA, Ferres M, et al. Molecular
576 method for the detection of Andes hantavirus infection: validation for clinical diagnostics.
577 *Diagn Microbiol Infect Dis.* 2016;84: 36–39.
- 578 46. Bolger AM, Lohse M, Usadel B. Trimmomatic: a flexible trimmer for Illumina sequence
579 data. *Bioinformatics.* 2014;30: 2114–2120.
- 580 47. Dobin A, Davis CA, Schlesinger F, Drenkow J, Zaleski C, Jha S, et al. STAR: ultrafast
581 universal RNA-seq aligner. *Bioinformatics.* 2013;29: 15–21.
- 582 48. Liao Y, Smyth GK, Shi W. featureCounts: an efficient general purpose program for
583 assigning sequence reads to genomic features. *Bioinformatics.* 2014;30: 923–930.
- 584 49. Robinson MD, Oshlack A. A scaling normalization method for differential expression
585 analysis of RNA-seq data. *Genome Biol.* 2010;11: R25.
- 586 50. Law CW, Alhamdoosh M, Su S, Dong X, Tian L, Smyth GK, et al. RNA-seq analysis is

- 587 easy as 1-2-3 with limma, Glimma and edgeR. F1000Res. 2016;5.
588 doi:10.12688/f1000research.9005.3
- 589 51. Robinson MD, McCarthy DJ, Smyth GK. edgeR: a Bioconductor package for differential
590 expression analysis of digital gene expression data. Bioinformatics. 2010;26: 139–140.
- 591 52. Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W, et al. limma powers differential
592 expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res.
593 2015;43: e47.
- 594 53. Weiner J 3rd, Domaszewska T. tmod: an R package for general and multivariate enrichment
595 analysis. PeerJ Preprints. 2016;4. Available:
596 https://pure.mpg.de/rest/items/item_2404004/component/file_2404003/content
- 597 54. Hart SN, Therneau TM, Zhang Y, Poland GA, Kocher J-P. Calculating sample size
598 estimates for RNA sequencing data. J Comput Biol. 2013;20: 970–978.

599

600

601 **Supporting Information captions**

602

603 **S1 Fig. Schematic overview of enrolled and analyzed individuals for this study.**

604

605 **S1 Table. Number of sequenced samples of HCPS patients and Healthy controls.**

606

607

608 **S2 Table. Significant DEGs belonging to marked BTMs from text Fig 3**

609

610 **S3 Table. Gene enrichment analysis: Biological processes and enriched genes in**
611 **ECMO/Fatal group of patients in early-acute-response, from Fig 4B**

612

613 **S4 Table. Correlations between transcriptional profile enriched in ECMO/Fatal patients in**
614 **an early acute response and clinical data.**

615

616 **S5 Table. Cell surface markers used to define WBC populations by flow cytometry**
617 **immunophenotyping.**

618

619 **Data reporting:** FastQ files from transcriptomic analysis are available at PRJNA660433. Any
620 metadata needed must be obtained through an MTA with the authors.

621 **Financial Disclosure Statement:** This research was funded by Agencia Nacional de
622 Investigación y Desarrollo (ANID) Projects Fondecyt 1161447, Fondecyt 1201240, Redes
623 180195; Concurso Interno VRID UDD2018, Universidad del Desarrollo.

624 **Competing interests:** The authors declare no conflict of interest.

625

626 **Related manuscripts:** The authors declare there is not a duplicated or related manuscript under
627 consideration or accepted for publication elsewhere.

628 **Author contributions:** Conceptualization C.V., P.V. and G.E.; methodology C.V., L.L. and GE;
629 patient enrollment M.F., N.L.C., C.M-V., L.F, M.L.R, J.G., F.A., J.G.,R.L.,J.L.P; formal analysis,
630 G.E. and L.L.; investigation, R.P., E.D.,C.M-V., P.V., A.C.; resources, P.V. and C.V.; data
631 curation, A.C.; writing original draft preparation, G.E, C.V. and L.L., writing review and editing,
632 N.L.C., M.C., G.M. and P.V.; project administration, R.P.; funding acquisition, G.M., P.V. and
633 C.V.

634

635

636

Table 1. Demographics, clinical and blood cells immunophenotypes of HCPS patients and healthy controls.

	HCPS – Severe Patients		Healthy Controls	P value
	MV+VD	ECMO/Fatal		
No. of patients	5	7	9	
Age (years), Median (25 to 75% IQR)	22 (10.0-26.50)	34 (15-36)	25 (17.0-40.50)	0.501 ^a
Gender, n (%)				
Male	5 (100)	4 (44.4)	5 (55.6)	0.193 ^b
Female	0	3 (37.5)	4 (44.4)	
Ethnicity, n (%)				
European	4 (80)	5 (71.4)	8 (88.9)	0.676 ^b
Amerindian	1 (20)	2 (28.6)	1 (11.1)	
Days of prodromal symptoms, Median (25 to 75% IQR)	6 (4.5-7.0)	6 (5.0-7.0)	NA	1.000 ^c
Days of Oxygen requirement	6 (2.0-7.5)	10 (4.0-19.0)	NA	0.149 ^c
Days of VD duration	3 (2.0-3.5)	7 (1.0-9.0)	NA	0.202 ^c
Days of MV duration	4 (3.0-5.5)	9 (4.0-16.0)	NA	0.106 ^c
Days of ECMO	0	4 (0-6.0)	NA	0.048 ^c
Days of Hospitalization	13 (9.5-21.5)	19 (4.0-59.0)	NA	0.876 ^c
Laboratory exams^d				
ANDV Viral Load (copies/ng RNA)	319.50 (82-557)	616 (285.5-3368.25)	NA	0.286 ^c
Platelets (cells/mm ³)	44500 (33250-51250)	79000 (47750-154500)	236000 (201500-253000)	0.002 ^a
Leukocytes (cells/mm ³)	14900 (10000-22300)	10850 (7175-15425)	6400 (5725-7575)	0.085 ^a
Neutrophils %	51 (47-60.47)	63.8 (37.03-81)	53 (51-61)	0.732 ^a
Blood cell immunophenotype*				
T cell panel (cells/mm³)				
CD3+ cells	734.97 (568.2-2384.37)	1216.39 (443.99-3390.33)	1234.33 (1018.27-1575.23)	0.866 ^a
CD4+ T helper cells	130.08 (114.87-419.53)	481.82 (197.12-1920.69)	926.42 (692.69-1308.09)	0.90 ^a
CD8+ cytotoxic T cells	633.95 (452.5-1977.55)	736.34 (246.51-1194.27)	302.99 (262.94-336.84)	0.297 ^a
NK cell panel (cells/mm³)				
CD56+ NK cells	83.85 (60.01-199.09)	462.45 (110.19-1243.82)	290.96 (191.72-763.20)	0.258 ^a

CD3- CD56+ NK Bright cells	2.26 (1.62-8.40)	45.97 (7.73-132.95)	17.52 (10.11-24.23)	0.098 ^a
CD3+ CD56+ NKT cells	67.39 (37.92-82.22)	96.73 (19.76-117.53)	42.62 (30.10-141.45)	0.753 ^c
B cell panel (cells/mm³)				
CD19+ LB cells	122.85 (94.18-411.87)	169 (84.29-731.69)	364.27 (211.37-421.74)	0.508 ^c

Abbreviations: HCPS, hantavirus cardiopulmonary syndrome; NA, not applicable; VD, vasoactive drugs; MV, mechanical ventilation; ECMO, extracorporeal membrane oxygenation; LOS, length of stay; n, number; LB, B lymphocytes. *Data shown represent the median (25 to 75% IQR) of the first sample from 12 HCPS, 5 VM+VD, 7 ECMO/Fatal and 9 Healthy controls; ^a Kruskal-Wallis test and ^b Chi-square test were used for comparisons between VM+VD, ECMO/Fatal, and healthy controls; ^c Mann-Whitney test was used for comparisons between VM+VD and ECMO/Fatal. ^d Data shown represents the median (25 to 75% IQR) of the first sample of each patient (Day 0-2/Early acute).

Fig. 1. Clinical course of severe HCPS patients. Y axis is patient ID, X axis are the days of evolution, with a highlight on disease timeline: early-acute, late-acute or convalescent phase. Light green bars are the days of onset of nonspecific symptoms. Day 0 represents onset of cardiopulmonary symptoms. Blue bars represent the days when patients required supplementary oxygen. Red bars represent days when patients developed HCPS, requiring vasoactive drugs and mechanical ventilation as treatment. Dark green bars represent patients requiring ECMO. Patients that required ECMO or died were sub-categorize to the ECMO/Fatal group. Less severe patients that required vasoactive drugs and mechanical ventilation were sub-categorize to VM+VD patients. Grey bars are the hospitalization days to recover. *samples taken, † patients who died. VD, vasoactive drugs; MV, mechanical ventilation; ECMO, extracorporeal membrane oxygenation.

Fig. 2. Transcriptional PBMC signature of HCPS patients by severity. (A) HCPS patients and healthy controls were divided in seven study groups from A to G (study groups inside figure legend). Transcriptional profile was graphed as a multidimensional scaling (MDS) plot, where X and Y axis represents the variability in global expression profile of the samples and each dot is a patient with the corresponding colour of the study group. (B) Number of differentially expressed genes (DEGs) between MV+VD and ECMO/Fatal HCPS patients in an early-late-convalescent phase versus healthy controls with adjusted p-value of 0.05 (FDR of 5 %) and exhibiting at least 2 log₂ fold change (log₂FC > 2) difference in expression levels. DEGs were obtained by comparing each study group of HCPS patients with the healthy control group. (C) Transcriptional signatures of DEGs of healthy controls, MV+VD and ECMO/Fatal HCPS patients in an early and late-acute and convalescent phase. Data are displayed in a heatmap format, where each column represents a patient and each row represents the expression value (log₂FC median centered) of each gene between all samples. Red indicates overexpression, blue indicates underexpression, and yellow indicates no difference in expression between samples. The total of DEGs between groups were plotted in the heatmap (439 transcripts). (D) The Venn diagram shows the number of shared and unique DEGs between MV+VD and ECMO/Fatal patients in an early and late-acute-phase versus healthy controls.

Fig. 3. Dynamics of VM+VD and ECMO/Fatal HCPS patient's response in PBMCs. BTM dot plot of differentially enriched BTMs in VM+VD and ECMO/Fatal HCPS patients, in early-late-convalescent-phases were compared with healthy controls. Y axis has the name and code of each BTM module, and X axis each study group. Activation of modules was tested using the FDR-ranked lists of genes generated by limma and applying the tmod test. Each comparison is in the intersection of lines of the X and Y axis. When a module is statistically significant ($p\text{-value} \leq 0.001$) it is represented by a pie chart in the intersection in which the proportion of significantly upregulated genes are shown in red and downregulated in blue. The grey portion of the pie represents genes that were not significantly differentially regulated. The effect size (enrichment) is proportional to its size which means that the larger the size of the pie, the greater the module enrichment. The significance of module activation ($p\text{-value}$) is proportional to the intensity of the color pie, which means that the greater the color intensity (stronger the red or blue color), the lower the $p\text{-value}$ and the greater the significance. Modules that were not statistically significant, were not plotted and are seen as the line cross of X and Y axis.

Fig. 4. Transcriptional profile of DEGs in VM+VD and ECMO/Fatal patients in an early-acute phase. (A). A total of 110 transcripts are displayed in a heatmap format, where each column represents the gene expression of a patient (five VM+VD, seven ECMO/Fatal and nine healthy controls); Each row represents expression value (log₂FC median centered) for each gene between all samples. First row corresponds to the colour of the study group (legend inside the figure). Red indicates overexpression, blue indicates underexpression, and yellow indicates no difference in expression between samples. **(B)** Results of biological processes enriched in ECMO/Fatal patients. Gene set enrichment analysis was performed for the 52 exclusive DEG in ECMO/Fatal patients in an early-acute-phase. Node size correlates with gene set size and edge widths indicate the number of shared genes. Red and blue color indicate more and less enrichment significance respectively.

Fig. 5. Correlations between transcriptional profile enriched in ECMO/Fatal patients in an early acute response and clinical laboratory data. X axis has clinical, laboratory data and immune profile information Y axis has the code of analyzed BTMs and to which biological process it belongs. Spearman correlation between expression median of genes over- or underexpressed per BTM data and clinical/lab/immune information was performed for VM+VD and ECMO/Fatal patients. The dot in the intersection of X and Y axis shows the correlation, if no dot is present there's no correlation. The intensity of the color in the dot indicates the strength of the Spearman's correlation coefficient (red positive correlation and blue negative correlation), and the dot size indicates the significance of the *P*-value. CD3, CD3+ cells; CD4+, T helper cells; CD8+, cytotoxic T cells; LB, B cells; LI.M75, antiviral interferon signature; LI.M127, type I interferon response; LI.M150, innate antiviral response; LI.M67, activated dendritic cells; LI.M165, enriched in activated dendritic cells; LI.S3, plasma cells surface signature.

Fig. 6. Increased type I IFN is a hallmark of disease severity in HCPS patients. After infection is established in an early-acute-phase, type I IFN response is expressively activated and insensitivity to IFN can happen in the more severe patients that are treated with ECMO or die. Also, other cells such as endothelial cells produce high levels of proinflammatory cytokines that contribute to exacerbated immune response in more severe patients. Less severe patients present a moderate interferon response which leads to an antiviral and controlled immune response. Created with Biorender.